Overview

An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy

Status:
Completed

Trial end date:
2005-04-01

Target enrollment:

Participant gender:

Summary

Study to assess changes in synovial tissue before and after treatment with Abatacept in subjects with RA who remained on their background disease modifying anti-arthritis medications but who have failed previous therapy with anti-TNF (tumor necrosing factor)blocking agents.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Abatacept